These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 35236838)
1. Pandemic-response adenoviral vector and RNA vaccine manufacturing. Kis Z; Tak K; Ibrahim D; Papathanasiou MM; Chachuat B; Shah N; Kontoravdi C NPJ Vaccines; 2022 Mar; 7(1):29. PubMed ID: 35236838 [TBL] [Abstract][Full Text] [Related]
2. Rapid development and deployment of high-volume vaccines for pandemic response. Kis Z; Kontoravdi C; Dey AK; Shattock R; Shah N J Adv Manuf Process; 2020 Jul; 2(3):e10060. PubMed ID: 33977274 [TBL] [Abstract][Full Text] [Related]
3. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs. Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275 [TBL] [Abstract][Full Text] [Related]
4. Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. Kis Z; Kontoravdi C; Shattock R; Shah N Vaccines (Basel); 2020 Dec; 9(1):. PubMed ID: 33374802 [TBL] [Abstract][Full Text] [Related]
5. Vaccines on demand, part II: future reality. Geall AJ; Kis Z; Ulmer JB Expert Opin Drug Discov; 2023 Feb; 18(2):119-127. PubMed ID: 36384351 [TBL] [Abstract][Full Text] [Related]
6. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
7. Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response. Joe CCD; Segireddy RR; Oliveira C; Berg A; Li Y; Doultsinos D; Scholze S; Ahmad A; Nestola P; Niemann J; Douglas AD Biotechnol Bioeng; 2024 Jan; 121(1):176-191. PubMed ID: 37747758 [TBL] [Abstract][Full Text] [Related]
8. Advancing mRNA technologies for therapies and vaccines: An African context. Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K Front Immunol; 2022; 13():1018961. PubMed ID: 36353641 [TBL] [Abstract][Full Text] [Related]
9. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant. Stavaru C; Onu A; Lupulescu E; Tucureanu C; Rasid O; Vlase E; Coman C; Caras I; Ghiorghisor A; Berbecila L; Tofan V; Bowen RA; Marlenee N; Hartwig A; Bielefeldt-Ohmann H; Baldwin SL; Van Hoeven N; Vedvick TS; Huynh C; O'Hara MK; Noah DL; Fox CB Hum Vaccin Immunother; 2016 Apr; 12(4):1009-26. PubMed ID: 26618392 [TBL] [Abstract][Full Text] [Related]
10. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. ; Ampofo WK; Baylor N; Cobey S; Cox NJ; Daves S; Edwards S; Ferguson N; Grohmann G; Hay A; Katz J; Kullabutr K; Lambert L; Levandowski R; Mishra AC; Monto A; Siqueira M; Tashiro M; Waddell AL; Wairagkar N; Wood J; Zambon M; Zhang W Influenza Other Respir Viruses; 2012 Mar; 6(2):142-52, e1-5. PubMed ID: 21819547 [TBL] [Abstract][Full Text] [Related]
11. mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions. Okuyama R Vaccines (Basel); 2023 Nov; 11(12):. PubMed ID: 38140142 [TBL] [Abstract][Full Text] [Related]
12. Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa. Farnós O; Gelaye E; Trabelsi K; Bernier A; Subramani K; Kallel H; Yami M; Kamen AA Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32604755 [TBL] [Abstract][Full Text] [Related]
13. Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture. Kis Z; Shattock R; Shah N; Kontoravdi C Biotechnol J; 2019 Jan; 14(1):e1800376. PubMed ID: 30537361 [TBL] [Abstract][Full Text] [Related]
14. Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. Sayedahmed EE; Elkashif A; Alhashimi M; Sambhara S; Mittal SK Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33019589 [TBL] [Abstract][Full Text] [Related]
18. The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions. Brown S; Brown T; Cederna PS; Rohrich RJ Plast Reconstr Surg Glob Open; 2020 Oct; 8(10):e3206. PubMed ID: 33173705 [TBL] [Abstract][Full Text] [Related]
19. A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016). Palkonyay L; Fatima H Vaccine; 2016 Oct; 34(45):5414-5419. PubMed ID: 27498212 [TBL] [Abstract][Full Text] [Related]
20. A global pandemic influenza vaccine action plan. Kieny MP; Costa A; Hombach J; Carrasco P; Pervikov Y; Salisbury D; Greco M; Gust I; LaForce M; Franco-Paredes C; Santos JI; D'Hondt E; Rimmelzwaan G; Karron R; Fukuda K Vaccine; 2006 Sep; 24(40-41):6367-70. PubMed ID: 17240560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]